{"id":"intermittent-cefoxitin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Phlebitis at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefoxitin works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. The intermittent dosing regimen refers to the administration schedule rather than a novel mechanism. It has broad-spectrum activity against gram-positive and gram-negative bacteria, including anaerobes.","oneSentence":"Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:32.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis"},{"name":"Intra-abdominal infections"},{"name":"Gynecological infections"}]},"trialDetails":[{"nctId":"NCT05755789","phase":"PHASE3","title":"Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-06-22","conditions":"Antibiotic Prophylaxis, Colorectal Surgery","enrollment":2000},{"nctId":"NCT02560207","phase":"PHASE4","title":"Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2015-11","conditions":"Critically Ill","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intermittent cefoxitin","genericName":"Intermittent cefoxitin","companyName":"Poitiers University Hospital","companyId":"poitiers-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis, Intra-abdominal infections, Gynecological infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}